Table 1.
Demographics of the study population (control group vs haemoadsorption therapy)
| Characteristic | Control group (n = 33) | Haemoadsorption group (n = 43) | p value |
|---|---|---|---|
| Age (years) | 62 (53, 74) | 63 (52, 71) | NS |
| Sex female/male | 4/29 | 12/31 | NS |
| Weight (kg) | 87 (78, 105) | 90 (75, 100) | NS |
| Septic focus | NS | ||
| Abdominal | 9 | 13 | |
| Catheter infection | 0 | 1 | |
| CNS | 1 | 0 | |
| Pulmonary | 16 | 13 | |
| Soft tissue | 2 | 7 | |
| Unclear | 5 | 5 | |
| Urinary tract | 0 | 4 | |
| CRP before CVVHDF (mg/l) (n = 33 vs 42) | 253 (173, 363) | 250 (167, 337) | NS |
| PCT before CVVHDF (ng/l) | 7 (2, 30) | 28 (11, 67) | 0.002 |
| IL-6 before CVVHDF (pg/ml) (n = 0 vs 41) | Not measured | 5000 (939, 5000) | |
| Noradrenaline before CVVHDF (µg/min) | 44 (38, 62) | 64 (48, 90) | 0.005 |
| Hydrocortisone administration | 82% | 81% | NS |
| APACHE II before CVVHDF initiation | 35 (33, 40) | 39 (36, 42) | 0.01 |
| Lowest MAP 24 h before CVVHDF | 65 (57, 73) | 53 (40, 65) | 0.03 |
| Lowest GCS 24 h before CVVHDF (estimated if patient already sedated) | 11 (3, 15) | 3 (3, 3) | NS |
CNS central nervous system, CRP C-reactive protein, PCT procalcitonin, IL-6 interleukins 6, CVVHDF continuous veno-venous haemodiafiltration, MAP middle arterial blood pressure, GCS Glasgow Coma Scale, NS not significant